License Your Technology or Start a Biotech Company?

Mike Hull • September 11, 2026

For university inventors, one of the most important commercialization decisions is whether to license the technology directly to an established company or form a startup to develop it further. Neither path is inherently better. The right choice depends on how much work remains between the current research asset and something industry is ready to buy, license, or acquire.

When Direct Licensing Can Make Sense

Direct licensing is attractive when an established company already has the development capabilities, market access, regulatory infrastructure, manufacturing, or distribution needed to commercialize the invention—and when the technology is mature enough to compete for internal resources.

  • The commercial application is clear.
  • The asset fits an existing company's strategic priorities.
  • The remaining development can be absorbed by the licensee.
  • There is enough evidence for a partner to justify diligence and internal sponsorship.
  • The inventor prefers scientific participation over company-building.

When a Startup Can Create More Value

A startup may be necessary when the technology is too early for a traditional licensee, when substantial validation is required, or when a focused team can create a more valuable asset before partnering. The startup becomes a vehicle for concentrating capital, talent, and development around the technology.


  • Industry feedback is positive but consistently asks for more data.
  • The technology supports a differentiated product that requires focused development.
  • Non-dilutive funding can support early de-risking.
  • The opportunity may expand into multiple products or a platform.
  • Creating a development-ready asset could materially improve future licensing economics.

Compare the Hidden Costs of Both Choices

Licensing may require less founder time and capital, but the technology can receive less attention inside a large company or may command modest economics if it is very early. Starting a company can preserve more upside and control, but it introduces financing, governance, hiring, regulatory, operational, and dilution risk.

Use Partner Feedback as Evidence

Before forming a company solely because licensing outreach has been slow, ask prospective partners what is missing. If several companies identify the same validation gap, that is useful information. A startup can be designed specifically to close that gap and return to the market with a stronger asset.

Consider a Staged Path

The choice does not always have to be permanent. A team may form a startup, obtain a license or option from the university, use grants to generate validation data, and then partner or sell the company after a defined milestone. Conversely, a research collaboration or option agreement can sometimes test strategic interest before full company formation.

BYB Takeaway

License when the market is ready to absorb the asset. Start a company when focused de-risking can materially increase the technology's value, expand its strategic options, or make it partner-ready.

Do not start a biotech company simply because you have an invention. Start one when the company itself is the best vehicle for creating the next stage of value.

How to Commercialize University Research

By Mike Hull • September 14, 2026
Commercialization requires a second layer of work: translating the discovery into a defined use case, protectable asset, development plan, evidence package, and funding strategy that a customer, licensee, investor, or strategic partner can act on.

What Is a Biotech Commercialization Plan?

By Mike Hull • September 13, 2026
It is the operating logic that explains how a scientific asset can move from its current state to a product that can be funded, licensed, approved, adopted, reimbursed, partnered, or sold.

How Much Validation Do You Need Before Raising Capital?

By Mike Hull • September 12, 2026
There is no universal amount of validation required before a biotech company raises capital. Investors fund risk, so a company does not need every question answered.

The Bootstrap Score™

By Mike Hull • September 10, 2026
The Bootstrap Score™ is a practical framework for asking a more useful question: how much of the commercial risk has been reduced around the science?

The Commercialization Gap™

By Mike Hull • September 9, 2026
A paper can establish an important scientific finding, while a buyer, investor, regulator, licensee, or strategic partner may still see substantial unanswered risk.

The Valley of Dilution™

By Mike Hull • September 8, 2026
There is another risk that receives less attention—the Valley of Dilution™. It occurs when a company raises expensive equity before key uncertainties have been reduced.

The Bootstrap Flywheel™

By Mike Hull • September 7, 2026
The Bootstrap Flywheel™ is a different model: use each small de-risking step to make the next step easier, cheaper, and more credible.

Biotech Funding Sequence: What Money Should You Raise First?

By Mike Hull • September 6, 2026
The most important financing question for an early biotech company is often not how much money to raise. It is what type of money should fund the next milestone.

When Should a Biotech Startup Raise Venture Capital?

By Mike Hull • September 5, 2026
Venture capital is not inherently too early or too expensive. It becomes expensive when founders use it to answer questions that could have been answered first with smaller or less dilutive resources.

What Is NIH TABA?

By Mike Hull • September 4, 2026
NIH Technical and Business Assistance—commonly called TABA—is designed to help SBIR and STTR recipients address product-development and commercialization needs that are often outside the core scientific aims of the award.